The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?

The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?

Bibliographic Details
Main Authors: Amy L. Cummings, Edward B. Garon
Format: Article
Language:English
Published: China Anti-Cancer Association 2017-08-01
Series:Cancer Biology & Medicine
Subjects:
Immunotherapy
immune checkpoint inhibitors
biomarkers
first-line treatment
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1069
id doaj-63004756d3e8447f87bcb9a14c465bae
record_format Article
spelling doaj-63004756d3e8447f87bcb9a14c465bae2020-11-24T22:00:37ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412017-08-0114434134710.20892/j.issn.2095-3941.2017.00902017000090The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?Amy L. Cummings0Edward B. Garon1Department of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles 90095, USADepartment of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles 90095, USAhttp://www.cancerbiomed.org/index.php/cocr/article/view/1069Immunotherapyimmune checkpoint inhibitorsbiomarkersfirst-line treatment
collection DOAJ
language English
format Article
sources DOAJ
author Amy L. Cummings
Edward B. Garon
spellingShingle Amy L. Cummings
Edward B. Garon
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
Cancer Biology & Medicine
Immunotherapy
immune checkpoint inhibitors
biomarkers
first-line treatment
author_facet Amy L. Cummings
Edward B. Garon
author_sort Amy L. Cummings
title The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
title_short The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
title_full The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
title_fullStr The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
title_full_unstemmed The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
title_sort ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
publisher China Anti-Cancer Association
series Cancer Biology & Medicine
issn 2095-3941
2095-3941
publishDate 2017-08-01
topic Immunotherapy
immune checkpoint inhibitors
biomarkers
first-line treatment
url http://www.cancerbiomed.org/index.php/cocr/article/view/1069
work_keys_str_mv AT amylcummings theascentofimmunecheckpointinhibitorsistheunderstudyreadyforaleadingrole
AT edwardbgaron theascentofimmunecheckpointinhibitorsistheunderstudyreadyforaleadingrole
AT amylcummings ascentofimmunecheckpointinhibitorsistheunderstudyreadyforaleadingrole
AT edwardbgaron ascentofimmunecheckpointinhibitorsistheunderstudyreadyforaleadingrole
_version_ 1725843692919455744

Similar Items